Gilead (GILD) Received FDA Orphan Drug Designation for Treatment to Prevent Mother to Child Transmission of Hepatitis B Virus.

September 30, 2016 8:21 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Gilead Sciences' (NASDAQ: GILD) tenofovir disoproxil fumarate was granted an Orphan Drug Designation for prevention of mother to child transmission of hepatitis B virus.

Generic Name: tenofovir disoproxil fumarate
Trade Name: Viread
Date Designated: 09/27/2016
Orphan Designation: Prevention of mother to child transmission of hepatitis B virus
Orphan Designation Status: Designated
FDA Orphan Approval Status:Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404

The sponsor address listed is the last reported by the sponsor to OOPD.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment